NPM1 and colitis: Compared with Npm1+/− mice without bezafibrate treatment during the course of DSS administration, Npm1+/− mice receiving bezabrifate exhibited greater recovery of body weight, greater reduction in DAI, longer colons and reduced inflammation (Fig. 4j–n), suggesting that maintaining mitochondrial function through bezafibrate limited colitis severity in Npm1+/− mice.